Pharmocology Flashcards
Mechanism of Action (MOA) of Selegiline
MAO-B selective inhibitor (MAO-B is the primary isoenzyme responsible for degradation of DA in the striatum).
Benefit of Selegiline selectivity
They inhibit DA metabolism in the striatum without greatly affecting degradation of catecholamines in other brain regions.
So decreased risk of hypertensive crisis due to accumulation of peripheral NE
what is responsible for insomnia side effectof selegiline
methamphetamine and amphetamine
Best use of selegiline
adjunctive agent to improve response to levodopa
selegiline interactions
TCAs, serotonin, SSRIs with an effect of serotonin syndrome (sympathetic activity with hyperthermia)
MOA of Rasagiline
MAO-B selective inhibitor; more neuroprotective than selegiline and maybe less behavioral side effects
Bromocriptine MOA
Ergot-derived dopamine agonists
SE (side effects) of Bromocriptine
Vasospasm. psychotomimetic and dyskinetic effects, profound nausea, vomiting
Pramipexole MOA
Affects D3 receptors as DA agonists, neuroprotective agent, both early and advanced PD
Ropinirole MOA
Selective D2 agonists; effective in early or advanced PD alone or combo
Anticholinergics
Biperiden
Trihexyphenidyl
Benztropine
Anticholinergics MOA
Centrally acting competitive inhibitor or muscarinic cholingeric receptors
Improve tremor and rigidity but not bradykinesia
SE of antimuscarinics
Dry mouth, urinary retention, constipation, will make demntia worse
CI (contraindications) of antimuscarinics
prostatic hyperplasia, obstructive GI disease, glaucoma
MOA of Amantadine
Facilitate DA function (poorly understood)
short lived benefits
SE of Amantadine
insomnia, restlessness, depression, GI disturbances, toxic psychosis in overdose
CI of Amantadine
seizure disorders, CHF
why use L-DOPA instead of DA
DA doesn’t penetrate the CNS but L-DOPA is the precursor that can be converted after transport by dopa decarboxylase
why is L-DOPA not use initially as much
Limited period of effectiveness of this drug
after substantial degeneration of DA neurons what drug could still be effective
direct dopamine receptor agonists becasue dont depend on functional capacity of DA neurons
difference between DA agonists and L-DOPA
DA agonists - reduce endogenous DA release and reduce need for exogenous levodopa
DA agonists should RETARD the disease progression whereas levodopa therapy would accelerate the progression (DA metabolism contributes to progression of the PD neurodegenerative process)
Carbidopa MOA
Does not cross blood brain barrier; it inhibits peripheral DA formation allowing levodopa dose to be lowered while increasing its availability to the CNS (allows levodopa dose to be lowered while increasing its availability to the CNS)
SE of Levodopa
GI: nausea and vomiting (tolerance after 4-6 weeks)
Cardio: arrhythmia due to increased catecholamines
Dyskinesia: chora, ballismus, athetosis, tics, tremor
Behavior: mood, hallucination, sleep disturbance
Drugs you can’t use to treat SE of levodopa
Phenothiazine: as antiemetics (DA receptor blocker)
Haloperidol: for dyskinesia (DA receptor blocker)
Conventional antipsychotics because anti-dopaminergic
MAOA Inhibitors